Proceeding contribution from Lord Lansley (Conservative) in the House of Commons on Thursday, 8 December 2005. It occurred during Estimates day on Department of Health.
Department of Health
Does the right hon. Gentleman agree that we should not assume that randomised control trials designed to establish the efficacy of drugs can always provide the same degree of assurance on a drug’s safety? Should not particular importance therefore be attached to the capture of data from whole populations after licensing, to establish the safety of the drug? It would be impractical to undertake that kind of evidence gathering from a substantial population before licensing.
Secondary information
- Type
- Proceeding contribution
- Reference
- 440 c1023
- Session
- 2005-06
- Chamber / Committee
- House of Commons chamber
- Subjects
- Advertising Licensing Expenditure Drugs Government departments Industry Prescription drugs Department of Health Medicines and Healthcare products Regulatory Agency Research Regulation Safety National Institute for Health and Care Excellence Registration Clinical trials
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2025-11-24 15:50:36 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285095
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285095
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285095